Showing results (141-150 of 368) with videos related to

Sort By:
Pageof 37
Diabetes Technology & Therapeutics|June 17, 2004
Experience with the continuous glucose monitoring system in a medical intensive care unitPhilip A Goldberg, Mark D Siegel, Raymond R Russell, et al.
Circulation|February 13, 2008
Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of riskMikhail Kosiborod, Silvio E Inzucchi, Harlan M Krumholz, et al.
Stroke|May 6, 2003
Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic strokeWalter N Kernan, Silvio E Inzucchi, Catherine M Viscoli, et al.
Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.
Diabetes & Vascular Disease Research|January 16, 2015
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trialsSilvio E Inzucchi, Bernard Zinman, Christoph Wanner, et al.
Diabetologia|March 5, 2022
Reversibility of brain glucose kinetics in type 2 diabetes mellitusElizabeth Sanchez-Rangel, Felona Gunawan, Lihong Jiang, et al.
The Journal of Clinical Endocrinology and Metabolism|May 16, 2019
In a Free-Living Setting, Obesity Is Associated With Greater Food Intake in Response to a Similar Premeal Glucose NadirJanice Kim, Wai Lam, Qinxin Wang, et al.
Kidney International|May 31, 2019
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamicsGert J Mayer, Christoph Wanner, Matthew R Weir, et al.
European Heart Journal|January 29, 2016
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trialDavid Fitchett, Bernard Zinman, Christoph Wanner, et al.
Circulation|September 15, 2017
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney DiseaseChristoph Wanner, John M Lachin, Silvio E Inzucchi, et al.
Pageof 37